Insulin Resistance-Pipeline Insights, 2014

News provided by

Aug 18, 2014, 02:00 ET

LONDON, Aug. 18, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Insulin Resistance-Pipeline Insights, 2014

https://www.reportbuyer.com/product/2278599/-Insulin-Resistance-Pipeline-Insights-2014.html

SUMMARY
DelveInsight's," Insulin Resistance-Pipeline Insights, 2014", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Insulin Resistance. This report provides information on the therapeutic development based on the Insulin Resistance dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Insulin Resistance
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Insulin Resistance pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Insulin Resistance and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Insulin Resistance
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Insulin Resistance pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Table of Contents
- Insulin Resistance Overview
- Insulin Resistance Pipeline Therapeutics
- Insulin Resistance Therapeutics under Development by Companies
- Insulin Resistance Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Insulin Resistance Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Insulin Resistance Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Insulin Resistance Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Insulin Resistance – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Insulin Resistance – Discontinued Products
- Insulin Resistance – Dormant Products
- Companies Involved in Therapeutics Development for Insulin Resistance
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Insulin Resistance, 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Insulin Resistance Assessment by Monotherapy Products
- Insulin Resistance Assessment by Combination Products
- Insulin Resistance Assessment by Route of Administration
- Insulin Resistance Assessment by Stage and Route of Administration
- Insulin Resistance Assessment by Molecule Type
- Insulin Resistance Assessment by Stage and Molecule Type
- Insulin Resistance Therapeutics – Discontinued Products
- Insulin Resistance Therapeutics – Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Insulin Resistance, 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Insulin Resistance Assessment by Monotherapy Products
- Insulin Resistance Assessment by Combination Products
- Insulin Resistance Assessment by Route of Administration
- Insulin Resistance Assessment by Stage and Route of Administration
- Insulin Resistance Assessment by Molecule Type
- Insulin Resistance Assessment by Stage and Molecule Type